KRN2

• Description :

  KRN2 is a selective inhibitor of nuclear factor of activated T cells (NFAT5), with an IC50 of 100 nM. KRN2 has potential to treat NFAT5-mediated Chronic Arthritis[1].

• UNSPSC :

  12352005

• Target :

  Nuclear Factor of activated T Cells (NFAT)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/KRN2.html

• Purity :

  98.04

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C(CC6=CC=CC=C6F)=C2C=C1.[Cl-]

• Molecular Formula :

  C27H23ClFNO4

• Molecular Weight :

  479.93

• References & Citations :

  [1]Han EJ, et al. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  J Immunol. 2021 Jun 1;206 (11) :2652-2667.|Johns Hopkins University. 2025.|Biomolecules. 2024 Nov 13;14 (11) :1444.|J Immunol. 2021 Jun 1;206 (11) :2652-2667.

• CAS Number :

  [248260-75-5]